US Esophageal Cancer Market

ID: MRFR/Pharma/14238-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
US Esophageal Cancer Market Research Report By Type (Esophageal Squamous-Cell Carcinoma, Esophageal Adenocarcinoma), By Phase (Phase I, Phase II, Phase III) and By Treatment (Surgery, Chemotherapy, Radiotherapy) - Growth & Industry Forecast 2025 To 2035
US Esophageal Cancer Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.68%
2024 Market Size$ 3,490.08 Million
2025 Market Size$ 3,758.11 Million
2035 Market Size$ 7,880 Million
Key Players
Bristol-Myers Squibb
Merck & Co
Roche
AstraZeneca
Eli Lilly and Company
Novartis
Trends
  • Emergence of Targeted Therapies
  • Increased Focus on Early Detection
  • Integration of Digital Health Solutions
Opportunities
  • Rising Incidence Rates
  • Increased Research Funding
  • Growing Awareness and Education
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Type (USD Million)
      1. 4.1.1 Esophageal Squamous-Cell Carcinoma
      2. 4.1.2 Esophageal Adenocarcinoma
    2. 4.2 Chemicals and Materials, BY Phase (USD Million)
      1. 4.2.1 Phase I
      2. 4.2.2 Phase II
      3. 4.2.3 Phase III
    3. 4.3 Chemicals and Materials, BY Treatment (USD Million)
      1. 4.3.1 Surgery
      2. 4.3.2 Chemotherapy
      3. 4.3.3 Radiotherapy
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Bristol-Myers Squibb (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Merck & Co (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 AstraZeneca (GB)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Eli Lilly and Company (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Novartis (CH)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Pfizer (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Amgen (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY PHASE
    4. 6.4 US MARKET ANALYSIS BY TREATMENT
    5. 6.5 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    8. 6.8 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    10. 6.10 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    11. 6.11 CHEMICALS AND MATERIALS, BY TYPE, 2024 (% SHARE)
    12. 6.12 CHEMICALS AND MATERIALS, BY TYPE, 2024 TO 2035 (USD Million)
    13. 6.13 CHEMICALS AND MATERIALS, BY PHASE, 2024 (% SHARE)
    14. 6.14 CHEMICALS AND MATERIALS, BY PHASE, 2024 TO 2035 (USD Million)
    15. 6.15 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 (% SHARE)
    16. 6.16 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY PHASE, 2025-2035 (USD Million)
      3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Esophageal Cancer Market Segmentation

US Esophageal Cancer Market By Type (USD Million, 2025-2035)

  • Esophageal Squamous-Cell Carcinoma
  • Esophageal Adenocarcinoma

US Esophageal Cancer Market By Phase (USD Million, 2025-2035)

  • Phase I
  • Phase II
  • Phase III

US Esophageal Cancer Market By Treatment (USD Million, 2025-2035)

  • Surgery
  • Chemotherapy
  • Radiotherapy

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.